In fibrotic disorders, the normal regulation of the extracellular matrix (ECM) is compromised, which leads to excess of ECM or lack of MMPs. This can further lead to a disorganized accumulation of ECM which can ultimately result in organ rigidity and fibrosis. For this reason, the ECM constitutive proteins, MMPs and fibroblasts activating and regulatory mediators such as TGF-β1 and PGE2 are hot spots of therapeutic research for fibrosis.
With this review, you will:
- Better understand how COX enzymes regulate PGE2 levels in TLR stimulated fibroblasts
- Learn how an AlphaLISA protein-protein interaction assay can be used as a screening platform for TG2-Fibronectin inhibitor identification
- Discover how CKD might impact the malignant myocardial fibrosis factor combination
